Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price due to concerns over milestone payments and clinical program continuity. Arrowhead's financial position remains strong, even with a reduced runway caused by the lack of promised milestone payments from Sarepta. In today's article, I discuss a range of potential outcomes for the collaboration between Sarepta Therapeutics and Arrowhead Pharmaceuticals and what Arrowhead can do with its pipeline and financials.

First BanCorp. (NYSE:FBP ) Q2 2025 Earnings Conference Call July 22, 2025 10:00 AM ET Company Participants Ramon Rodriguez - Senior Vice President of Corporate Strategy / Investor Relations Aurelio Aleman-Bermudez - President, CEO & Director Orlando Berges-González - Executive VP & CFO Conference Call Participants Brett D. Rabatin - Hovde Group, LLC, Research Division Timur Felixovich Braziler - Wells Fargo Securities, LLC, Research Division Kelly Ann Motta - Keefe, Bruyette, & Woods, Inc., Research Division Operator Hello, and welcome, everyone, to the First BanCorp 2Q 2025 Financial Results.

DURHAM, N.C., July 22, 2025 (GLOBE NEWSWIRE) -- Aspida Life Re Ltd (“Aspida Re”), a Bermuda-based life and annuity reinsurance company, announced the execution of its second reinsurance transaction in Japan, effective June 1, 2025. This milestone marks a significant step in Aspida Re's ongoing strategy to expand its global footprint and deliver innovative reinsurance solutions to life and annuity insurance partners worldwide.

Avery Dennison Corporation (NYSE:AVY ) Q2 2025 Earnings Call July 22, 2025 11:00 AM ET Company Participants s - Corporate Participant e - Corporate Participant d - Corporate Participant Deon M. Stander - President, CEO & Director Gregory S.

The Magnificent Seven group of tech stocks, as a whole, may still be fantastic long-term bets.

BOKF beats Q2 estimates as net interest income and loan growth lift results, despite rising costs and weaker deposits.

The increasing acceptance of Bitcoin as a store of value benefits MSTR and RIOT. Find out which stock is leading now.

CrowdStrike deepens its AI security focus with new agentic tools and AWS ties.

Neils Christensen has a diploma in journalism from Lethbridge College and has more than a decade of reporting experience working for news organizations throughout Canada. His experiences include covering territorial and federal politics in Nunavut, Canada.

Invesco Ltd. (NYSE:IVZ ) Q2 2025 Earnings Call July 22, 2025 9:00 AM ET Company Participants Andrew Ryan Schlossberg - President, CEO & Director Gregory Wade Ketron - Head of Investor Relations & Treasury Laura Allison Dukes - Senior MD & CFO Conference Call Participants Alexander Blostein - Goldman Sachs Group, Inc., Research Division Benjamin Elliot Budish - Barclays Bank PLC, Research Division Brian Bertram Bedell - Deutsche Bank AG, Research Division Glenn Paul Schorr - Evercore ISI Institutional Equities, Research Division Kenneth Brooks Worthington - JPMorgan Chase & Co, Research Division Michael J.

IPG posts 23% y/y EPS growth in second-quarter 2025. Yet, revenues slip 6.7% and margins face sharp y/y declines.

Fulton Financial (FULT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Interactive Brokers Group, Inc. (IBKR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

The Charles Schwab Corporation (SCHW) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

The company ORCL-2.37% is helping OpenAI boost its artificial-intelligence data-center capacity, and analysts at Evercore ISI are doing the math about how much that will cost Oracle as it pursues the potential for $30 billion in annualized revenue down the road.

Danaher Corporation (NYSE:DHR ) Q2 2025 Earnings Conference Call July 22, 2025 8:00 AM ET Company Participants John Bedford - Vice President of Investor Relations Matthew R. McGrew - CFO & Executive VP Rainer M.

ATLANTA, July 22, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) complied with federal securities laws. On July 22, 2025, Replimune announced it received a Complete Response Letter (“CRL”) from the FDA regarding the Biologics License Application (“BLA”) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. In the CRL, the FDA indicated “that the IGNYTE trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness.” Following this news, the price of the Company's stock …

Tesla Inc (NASDAQ:TSLA) will hand down its second quarter earnings this week amid a dramatically different backdrop than just three months ago, according to Wedbush analysts. “While near-term and this quarter the numbers are nothing to write home about, we believe investors are instead focused on the AI future at Tesla with a motivated [CEO Elon] Musk back driving Tesla's future,” the firm wrote.

West Pharmaceutical targets steady Q2 growth as high-value GLP-1 and SmartDose demand drives segment momentum.

RLI's quarterly results reflect higher premium earned and improved investment income, offset by escalating expenses and poor underwriting income.